Aktuelle Standards und vielversprechende Innovationen in der medikamentösen Zweitlinientherapie des metastasierten kleinzelligen Lungenkarzinoms (ED-SCLC)
Author:
Publisher
Springer Science and Business Media LLC
Link
https://link.springer.com/content/pdf/10.1007/s00761-024-01579-y.pdf
Reference29 articles.
1. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med 379(23):2220–2229. https://doi.org/10.1056/NEJMoa1809064 (Epub 2018 Sep 25. PMID: 30280641)
2. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929–1939. https://doi.org/10.1016/S0140-6736(19)32222-6 (Epub 2019 Oct 4)
3. Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE et al (2021) Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32(7):839–853. https://doi.org/10.1016/j.annonc.2021.03.207 (Epub 2021 Apr 20. PMID: 33864941)
4. Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G et al (2022) Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3‑year overall survival update from CASPIAN. ESMO Open 7(2):100408. https://doi.org/10.1016/j.esmoop.2022.100408 (Epub 2022 Mar 10.PMID: 35279527)
5. Liu SV, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F et al (2023) Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella A extension study results. Presented at WCLC 2023. Abstract #OA01.04. J Thorac Oncol 18(Supp 11):S44–S45. https://doi.org/10.1016/j.jtho.2023.09.025
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3